Drug intelligence / Profile preview

NCO-48F

Development stage: Phase 1
Lead developer: Jibao Pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

NCO-48F is an investigational small molecule capsid assembly modulator (CAM) being developed by Guangdong Jibao Pharmaceutical Technology for the treatment of chronic hepatitis B (CHB). It targets the Hepatitis B virus (HBV) core protein (HBcAg), a critical component for viral capsid assembly, pregenomic RNA (pgRNA) encapsidation, and viral DNA replication. NCO-48F acts by misdirecting the assembly process, leading to the formation of empty or defective capsids that are unable to support viral replication. This mechanism is distinct from nucleos(t)ide analogs (NAs), which inhibit the viral polymerase, making NCO-48F a potential candidate for combination therapies aimed at achieving a functional cure for HBV. The drug is currently in early-phase clinical development in China.

Targets

HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on NCO-48F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCO-48F.